You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al
  1. Sofia Ramiro1,
  2. Josef S Smolen2,3,
  3. Robert B M Landewé4,5,
  4. Désirée van der Heijde1,
  5. Laure Gossec6,7
  1. 1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2 Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
  3. 3 Department of Medicine, Hietzing Hospital, Vienna, Austria
  4. 4 Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands
  5. 5 Zuyderland Hospital, Heerlen, The Netherlands
  6. 6 UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), Sorbonne Universités, Paris, France
  7. 7 Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France
  1. Correspondence to Dr Sofia Ramiro, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, Leiden, The Netherlands; sofiaramiro{at}gmail.com

http://dx.doi.org/10.1136/annrheumdis-2017-212012

Statistics from Altmetric.com

    We thank Tillet et al for their comments1 on our letter to the editor entitled ‘How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review’.2 We appreciate that the authors are in agreement with our view regarding the clear need for the …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

    Linked Articles